только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 5 / 5
Страница 1 / 1

Список литературы

  1. Алехин М.Н. Значение эхокардиографии у пациентов с артериальной гипертензией / М.Н. Алехин // Кардиология. 2018. № 1. С. 90–100.
  2. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25. № 3. С. 149–218.
  3. Верткин А.Л., Скотников А.С., Прохорова Ю.В. Роль алгоритмизации назначения гипотензивной терапии и совершенствования методики повышения квалификации врачей в лечении артериальной гипертензии // Справочник врача общей практики. 2016. № 5. С. 5–17.
  4. Дума С.Н., Щербакова Л.В. Диагностика и лечение психогенного головокружения у больных артериальной гипертензией // Журнал неврологии и психиатрии имени С.С. Корсакова. 2016. Т. 116. № 2. С. 62–66.
  5. Клинические рекомендации РКО // Артериальная гипертензия у взрослых. М.: 2020. 136 с.
  6. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. // Российский кардиологический журнал. 2018. № 12. С. 131–142.
  7. Скотников А.С., Юдина Д.Ю., Стахнев Е.Ю. Гипотензивная терапия коморбидного больного: на что ориентироваться в выборе лекарственного средства? // Лечащий врач. 2018. № 2. С. 24–30.
  8. Albasri A,. O’Sullivan J.W., Roberts N.W. et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis // Journal of hypertension. 2017. Vol. 35. N. 10. P. 1919–1928.
  9. Carey R.M., Calhoun D.A., Bakris G.L. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association // Hypertension. 2018. Vol. 72. N. 5. P. e53–e90.
  10. Easterling T., Mundle S., Bracken H. et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomized controlled trial // The Lancet. 2019. Vol. 394. N. 10203. P. 1011–1021.
  11. Garjón J., Saiz L.C., Azparren A. et al. First‐line combination therapy versus first‐line monotherapy for primary hypertension // Cochrane Database of Systematic Reviews. 2017. N. 1. doi: 10.1002/14651858.CD010316.pub2.
  12. Garrison S.R., Kolber M.R., Korownyk C.S. et al. Blood pressure targets for hypertension in older adults // Cochrane Database of Systematic Reviews. 2017. N. 8. doi: 10.1002/14651858.CD011575.pub2.
  13. Gottesman R.F., Albert M.S., Alonso A. et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Ather­osclerosis Risk in Communities (ARIC) cohort // JAMA Neurol. 2017. Vol. 74. P. 1246–1254.
  14. Lehtonen A.O., Puukka P., Varis J. et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals // J. Hypertens. 2016. Vol. 34. P. 959–966.
  15. Lip G.Y.H., Coca A., Kahan T. et al. Hypertension and cardiac arrhy­thmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific HeartRhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE) // Eur. Heart. J. Cardiovasc Pharmacother. 2017. Vol. 3. P. 235–250.
  16. MacDonald T.M., Williams B., Webb D.J. et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial // J. Am. Heart. Assoc. 2017. Vol. 6. P. e006986.
  17. Mathiassen O.N., Vase H., Bech J.N. et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial // J. Hypertens. 2016. Vol. 34. P. 1639–1647.
  18. Pongpanich P., Pitakpaiboonkul P., Takkavatakarn K. et al. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis // International urology and nephrology. 2018. Vol. 50. N. 12. P. 2261–2278.
  19. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagno- sis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with thespecial contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart. J. 2016. Vol. 37. P. 2129–2200.
  20. Reino-Gonzalez S., Pita-Fernández S., Seoane-Pillado T. et al. How in-office and ambulatory BP monitoring compare: A systematic review and meta-analysis // J. Fam. Pract. 2017. Vol. 66. N. 1. P. E5–E12..
  21. Salles G.F., Reboldi G., Fagard R.H. et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis // Hypertension. 2016. Vol. 67. P. 693–700.
  22. Soliman E.Z., Ambrosius W.T., Cushman W.C. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial) // Circulation. 2017. Vol. 136. N. 5. P. 440–450.
  23. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9 Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials // J. Hypertens. 2016. Vol. 34. P. 1921–1932.
  24. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowe­ring on outcomeincidence in hypertension: 7 Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and meta-analyses of randomized trials // J. Hypertens. 2016. Vol. 34. P. 613–622.
  25. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12 Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials // J. Hypertens. 2017. Vol. 35. P. 2150–2160.
  26. Tucker K.L., Sheppard J.P., Stevens R. et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis // PLoS Med. 2017. Vol. 14. P. e1002389.
  27. Vidal-Petiot E., Ford I., Greenlaw N. et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study // The Lancet. 2016. Vol. 388. N. 10056. P. 2142–2152.
  28. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the ma­nagement of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the ma­nagement of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension // J. Hypertens. 2018. Vol. 36. N. 10. P. 1953–2041.
  29. Williamson J.D., Supiano M.A., Applegate W.B. et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >_75 years: a randomized clinical trial // JAMA. 2016. Vol. 315. P. 2673–2682.
  30. Zachrisson K., , Herlitz H., Lönn L. et al. Duplex ultrasound for identifying renal artery stenosis: direct criteria reevaluated // Acta Radiologica. 2017. Vol. 58. N. 2. P. 176–182.

Для продолжения работы требуется вход / регистрация